Marbocyl Bolus 50 mg Tablet

البلد: أيرلندا

اللغة: الإنجليزية

المصدر: HPRA (Health Products Regulatory Authority)

العنصر النشط:

Marbofloxacin

متاح من:

Vetoquinol Ireland Limited

ATC رمز:

QJ01MA93

INN (الاسم الدولي):

Marbofloxacin

جرعة:

50 mg/tablet

الشكل الصيدلاني:

Bolus

نوع الوصفة الطبية :

POM: Prescription Only Medicine as defined in relevant national legislation

المجموعة العلاجية:

Cattle

المجال العلاجي:

marbofloxacin

الخصائص العلاجية:

Antibacterial

الوضع إذن:

Authorised

تاريخ الترخيص:

1999-08-23

خصائص المنتج

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Marbocyl Bolus 50 mg Tablet
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Tablet.
Off white bolus shaped convex tablet.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle (neonatal calves).
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Marbocyl bolus is indicated in the treatment of neonatal
gastroenteritis caused by_ Escherichia coli_, in calves of 25-50 kg.
4.3 CONTRAINDICATIONS
None.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Do not exceed the recommended duration of treatment (3 days)
Each tablet contains:
ACTIVE SUBSTANCE:
Marbofloxacin
50.00 mg
For a full list of excipients, see section 6.1
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_1_
_9_
_/_
_1_
_0_
_/_
_2_
_0_
_1_
_6_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_3_
_4_
_5_
_5_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
When administration is carried out using an applicator, care should be
taken to avoid soft tissue injury.
Official and local antimicrobial policies should be taken into account
when the product is used. Fluoroquinolones should be
reserved for
the treatment
of
clinical
conditions which have responded poorly,
to other
classes of
antimicrobials.
Whenever possible,
fluoroquinolones should only be used based on susceptibility testing.
Use of the product deviating
from the instructions given in the SPC may increase the prevalence of
bact